The invention belongs to the field of medicine, in particular to a elbasvir derivative of deuterium modified, a pharmaceutical composition containing the compound and its use in the preparation of a drug for the treatment of HCV infection. The deuterium modified elbasvir derivatives of the present invention have more excellent properties in one or more measurements, such as activity determination, pharmacokinetic determination, liver microsomal metabolic stability, and so on. It is expected to reduce the dosage of clinical use and reduce the cost of treatment to benefit more patients.
【技术实现步骤摘要】
【国外来华专利技术】PCT国内申请,说明书已公开。
【技术保护点】
PCT国内申请,权利要求书已公开。
【技术特征摘要】
【国外来华专利技术】2015.12....
【专利技术属性】
技术研发人员:张寅生,敖汪伟,
申请(专利权)人:正大天晴药业集团股份有限公司,
类型:发明
国别省市:江苏,32
还没有人留言评论。发表了对其他浏览者有用的留言会获得科技券。